1	
2	
3	
4	
5	
6	
7	
8	
	Potrospostivo in cilico HI A prodictions from COVID 10 potients
9	Retrospective <i>in silico</i> HLA predictions from COVID-19 patients
10	reveal alleles associated with disease prognosis
11	
12	
13	René L. Warren and Inanç Birol
14 15	
13 16	
17	
18	
19	
20	René L. Warren
21	Genome Sciences Centre, BC Cancer
22	Vancouver, BC, V5Z 4S6, Canada
23	rwarren@bcgsc.ca
24 25	570 W 7th Ave #100, Vancouver, BC V5Z 4S6 (604) 707-5900 #673235
23 26	(004) 707-5900 #075255
20 27	*To whom correspondence should be addressed
28	
29	
30	Inanç Birol
31	Genome Sciences Centre, BC Cancer
32	Vancouver, BC, V5Z 4S6, Canada
33 34	ibirol@bcgsc.ca
34 35	
55	
36	
37	
•	
38	Keywords (8): COVID-19, SARS-CoV-2, Human Leukocyte Antigen (HLA), RNA-seq,
39	DPA1*02:02, A*11:01, C*04:01, DQA1*01:02
59	$\Box(A) \forall z.\forall z, A 1.\forall 1, \forall \forall 4.\forall 1, \forall QA \forall 1.\forall z$

40 **ABSTRACT**

Background: The Human Leukocyte Antigen (HLA) gene locus plays a fundamental 41 42 role in human immunity, and it is established that certain HLA alleles are disease 43 determinants. **Methods:** By combining the predictive power of multiple *in silico* HLA predictors, we 44 45 have previously identified prevalent HLA class I and class II alleles, including 46 DPA1*02:02, in two small cohorts at the COVID-19 pandemic onset. Since then, newer 47 and larger patient cohorts with controls and associated demographic and clinical data 48 have been deposited in public repositories. Here, we report on HLA-I and HLA-II alleles, along with their associated risk significance in one such cohort of 126 patients, including 49 50 COVID-19 positive (n=100) and negative patients (n=26). 51 **Results:** We recapitulate an enrichment of DPA1*02:02 in the COVID-19 positive 52 cohort (29%) when compared to the COVID-negative control group (Fisher's exact test 53 [FET] p=0.0174). Having this allele, however, does not appear to put this cohort's 54 patients at an increased risk of hospitalization. Inspection of COVID-19 disease severity 55 outcomes reveal nominally significant risk associations with $A^{+11:01}$ (FET p=0.0078). 56 C*04:01 (FET p=0.0087) and DQA1*01:02 (FET p=0.0121). 57 **Conclusions:** While enrichment of these alleles falls below statistical significance after 58 Bonferroni correction, COVID-19 patients with the latter three alleles tend to fare worse 59 overall. This is especially evident for patients with C*04:01, where disease prognosis 60 measured by mechanical ventilation-free days was statistically significant after multiple

61 hypothesis correction (Bonferroni p = 0.0023), and may hold potential clinical value.

62 INTRODUCTION

63

64 Modern history has been plaqued by deadly outbreaks, from the recurring influenza (e.g. Spanish, Asian, Hong Kong, Avian) and HIV/AIDS viral pandemics, to bacterial 65 and protist infections causing tuberculosis and malaria. Since the early 2000s, we have 66 67 faced another threat: novel coronavirus infections causing severe respiratory illnesses 68 such as SARS, MERS and today, coronavirus disease 2019 - COVID-19 [1]. The 69 SARS-CoV-2 coronavirus responsible for the COVID-19 respiratory disease is of 70 particular concern; not only does SARS-CoV-2 spread quickly, the symptoms of its 71 infection, when exhibited, are very similar to that of the cold and flu making it difficult to 72 diagnose, trace and contain. Further, infected individuals are affected differently. For 73 instance, older men (\geq 65 years old) with pre-existing medical conditions, such as 74 diabetes, appear at increased risk of progressing into the more severe phase of the 75 disease, yet SARS-CoV-2 infections affect all other age groups evenly except 76 occasionally in children and adolescents [2]. Most peculiar is that a high proportion of 77 individuals who tested positive for SARS-CoV-2 are asymptomatic – as high as 43% 78 recorded in Iceland, a rate that appears to vary depending on jurisdictions and 79 populations [3-5]. As of now, the disparity in patient response to SARS-CoV-2 infection 80 is still eluding us. 81 The most efficient way to combat pathogens has been through the use of our 82 own defense mechanism: our acquired immunity. This is done by vaccination

campaigns that effectively prime our immune systems at the population level before we
even encounter pathogens. But design of effective vaccines must consider interactions

85 with host immune genes. The Human Leukocyte Antigens (HLA) are a group of such 86 genes encoding surface receptors that bind short peptide epitopes derived from 87 endogenous (class I) or exogenous (class II) antigens, including viral antigens, and they 88 facilitate killer or helper T cells to set off an appropriate immune response. The 89 magnitude of this response varies between patients as populations and individuals have 90 different composition of HLA genes and variable T cell repertoires. As such, HLA 91 induces a bias, which is responsible for documented host susceptibility to disease [6]. 92 Some of the notable associations between HLA and disease are observed in AIDS 93 patients, with certain HLA alleles conferring protection [7]. In other cases, HLA has been 94 implicated with autoimmune diseases and diabetes [8-11]. The exact underlying 95 mechanisms behind these associations are unclear, but there is mounting evidence that 96 bacterial and viral infection may be the trigger for some [10] and that HLA plays a critical 97 role in the viral infection cycle, including viral entry into host cells [12]. 98 Since the beginning of the pandemic, worldwide reports have emerged on HLA 99 associations with COVID-19, including our own [13-19]. Using publicly available 100 metatranscriptomic sequencing data made available at the pandemic onset, we had 101 demonstrated the utility of a high throughput in silico method for characterizing the HLA 102 types of COVID-19 patients from bronchoalveolar lavage fluid and blood samples and 103 reported on prevalent alleles, including the DPA1*02:02P - DPB1*05:01P HLA-II 104 haplotype observed in 7 out of the 8 of patients from two small cohorts. Here, using 105 public RNA-seq sequencing data from a larger COVID-19 patient cohort with clinical 106 outcomes and demographics data [20], we report on HLA alleles with potential 107 diagnostic (DPA1*02:02) and prognostic (A*11:01 and C*04:01) value in 126

- 108 hospitalized patients with (n=100) and without (n=26) COVID-19 and present our
- 109 findings in light of available demographic characteristics using hospitalization and
- 110 disease severity metrics.

111 METHODS

113	We downloaded Illumina NOVASEQ-6000 paired-end (50 bp) RNA-Seq reads from					
114	libraries prepared from the blood samples of 126 hospitalized patients, with (n=100) or					
115	without COVID-19 (n=26) (ENA project: PRJNA660067, accessions: SRX9033799-					
116	SRX9033924). This data is part of a large-scale multi omics study from the Department					
117	of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, USA, with					
118	aims to analyze COVID-19 Severity and clinical as well as demographics data was					
119	made available by the study authors [20] (GEO accession GSE157103). On each					
120	patient RNA-Seq dataset, we ran HLA prediction software OptiType [21] (v1.3.4),					
121	seq2HLA [22] (v2.3), and HLAminer [23] (v1.4 targeted assembly mode with defaults)					
122	as described [19]. We tallied HLA class I (HLA-I) and class II (HLA-II, supported by					
123	Seq2HLA and HLAminer only) allele predictions and for each patient we report the most					
124	likely HLA allele (4-digit resolution), indicating HLA predictor tool support (Additional					
124 125	likely HLA allele (4-digit resolution), indicating HLA predictor tool support (Additional file 1, tables S1 and S2).					
125	file 1, tables S1 and S2).					
125 126	file 1, tables S1 and S2). Looking at class I and II alleles predicted in 10% or more of COVID-19 positive					
125 126 127	file 1, tables S1 and S2). Looking at class I and II alleles predicted in 10% or more of COVID-19 positive patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first					
125 126 127 128	file 1, tables S1 and S2). Looking at class I and II alleles predicted in 10% or more of COVID-19 positive patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first testing for enrichment in COVID-19 positive vs. negative patients (R function fisher.test,					
125 126 127 128 129	file 1, tables S1 and S2). Looking at class I and II alleles predicted in 10% or more of COVID-19 positive patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first testing for enrichment in COVID-19 positive vs. negative patients (R function fisher.test, alternative = "greater"). For those same alleles (found in ≥10% patients) and inspecting					
 125 126 127 128 129 130 	file 1, tables S1 and S2). Looking at class I and II alleles predicted in 10% or more of COVID-19 positive patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first testing for enrichment in COVID-19 positive vs. negative patients (R function fisher.test, alternative = "greater"). For those same alleles (found in ≥10% patients) and inspecting only the COVID-19 positive cohort, we tested for the probability of patient					
 125 126 127 128 129 130 131 	file 1, tables S1 and S2). Looking at class I and II alleles predicted in 10% or more of COVID-19 positive patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first testing for enrichment in COVID-19 positive vs. negative patients (R function fisher.test, alternative = "greater"). For those same alleles (found in ≥10% patients) and inspecting only the COVID-19 positive cohort, we tested for the probability of patient hospitalization, as measured by the Intensive Care Unit (ICU) metric reported by the					

135 post 45 day followup (days)" (HFD-45) metric reported by the study author as a proxy 136 for disease severity, with lower HFD-45 numbers indicating worse outcomes. Similarly, 137 we ran the KM estimator using another metric of disease severity, "ventilator-free days", 138 which captures the most severe cases with COVID-19 patients suffering respiratory 139 deterioration and requiring mechanical ventilation. On each set we calculated the log-140 rank p-value (R library survminer) and corrected for multiple hypothesis testing 141 (Bonferroni correction) using the number and patient abundance rank of class I (n=17) 142 or class II (n=11) HLA alleles observed in 10% or more of COVID-19 patients. We also 143 inspected the combined influence of HLA alleles and patient demographics data (age, 144 sex, ethnicity) on the hospitalization (ICU negative vs. positive) outcomes of COVID-19 145 patients, using odds-ratio calculations (R function fisher.test, and applying Haldane 146 correction [24] on zero values, when necessary).

147**RESULTS**

148

149 We collated the HLA class I and class II predictions of three in silico HLA predictors 150 derived from the RNA-seq samples of a recent [20] COVID-19 positive patient cohort 151 (n=100) with control patients (n=26) who tested negative for COVID-19 (Additional file 152 1, Tables S1 and S2). Due to the limiting short read length (paired 50 bp) we chose to 153 first report on OptiType [21] and seg2HLA [22] class I and class II predictions, and count 154 the additional allele support from seq2HLA and HLAminer [23]. In all, we identify 17 and 155 11 HLA class I and class II alleles predicted in 10% or more of COVID-19 patients. 156 respectively (Tables 1 and 2). There were many more alleles predicted (133 class I and 157 101 class II in the COVID-19 positive cohort), but too few patients are represented at 158 lower cut-offs to compute meaningful statistics. First, we looked at the statistical 159 enrichment (Fisher's Exact Test - FET) of each allele in the COVID-19 positive set. 160 compared to the COVID-19 negative control group. We find HLA-I A*30:02 and HLA-II 161 DPA1*02:02 allele enrichments nominally significant (FET p = 0.0417 and p = 0.0174) 162 at the 5% level (Tables 1 and 2). However, when Bonferroni correction is applied for 163 the number of HLA class I allele tests or when the abundance rank is factored in for 164 A*30:02, the test is not significant (n=17, Bonferroni p = 0.7080; n=10, Bonferroni p =165 0.4165, respectively). For HLA-II DPA1*02:02, Bonferroni correction finds the test 166 insignificant at the α =0.05 level for the number of hypothesis, but significant for the 167 allele abundance rank (n=11, Bonferroni p = 0.1916; n=2, Bonferroni p = 0.0348). 168 COVID-19 positive patients could be further stratified into those who were 169 hospitalized and admitted to the Intensive Care Unit (Tables I and 2, ICU+), and those 170 who were not (Tables 1 and 2, ICU-). When computing FET statistics, we find HLA-I

171	A*11:01 and C*04:01 and HLA-II DQA1*01:02 significant at the α =0.05 level (Tables 1
172	and 2 ; p = 0.0078, p = 0.0087 and 0.0121, respectively) but none remain significant
173	after Bonferroni correction. The Overmyer study authors [20] reported important disease
174	severity metrics (HFD-45 and days without needing mechanical ventilation), which we
175	used to assess the remission probability of COVID-19 patients having a specific allele
176	using Kaplan-Meier estimation. We find patients of the Overmyer cohort with either
177	A*11:01 (Figure1a), C*04:01 (Figure 1b) or DQA1*01:02 (Figure 1c) to be at a
178	significant increased risk of hospitalization (log-rank p = 0.0099 , p = 0.0082 and p =
179	0.0097). When applying multiple test corrections to account for allele abundance rank,
180	only C*04:01 (n=5, Bonferroni p = 0.0410) and DQA1*01:02 (n=2, Bonferroni p =
181	0.0194) remained significant at the $lpha$ =0.05 level. When looking at patients needing
182	mechanical ventilators, a severe outcome in COVID-19 disease progression, we only
183	find patients with C*04:01 to be at a statistically significant increased risk (Figure 1d,
184	log-rank p = 0.0019). Multiple hypothesis test correction retains the statistical
185	significance of this allele when factoring both the number of HLA-I alleles tested and
186	C*04:01 abundance rank (n=17, Bonferroni p = 0.0023; n=5, Bonferroni p = 0.0095).
187	Looking at the influence of the aforementioned alleles in combination with simple
188	demographics (sex, age and ethnicity), we find that of the Overmyer cohort patients with
189	the DPA1*02:02 allele, those with a white ethnic background and females appear at an
190	increased risk of testing positive for COVID-19 (Figure 2; odds ratio [OR] = 6.33 [5.33–
191	7.34], FET p = 0.0491 and OR = 7.33 [6.18-8.48], FET p = 0.0326, respectively). The
192	association with gender is also observed in alleles A*11:01, C*04:01 and DQA1:01:02,
193	putting female COVID-19 patients of this cohort at an increased risk of hospitalization

- 194 for the class I alleles (Figure 2; OR = 12.09 [10.41-13.76], FET p = 0.0105 for both) and 195 male COVID-19 patients at increased risk for DQA1*02:02 (Figure 2; OR = 2.74 [2.69-196 2.79], FET p = 0.0481). For patients with the latter HLA-II allele, minorities and younger 197 individuals (<65 years old) are also more at risk of hospitalization (Figure 2; OR = 4.08 198 [2.85-5.32], FET p = 0.0222 and OR = 3.62 [2.42-4.83], FET p = 0.0240, respectively). 199 In this cohort, we also find patients with A*11:01 in the younger age group (<65 years 200 old) at increased risk of hospitalization (Figure 2; OR = 9.54 [8.14-10.94], FET p = 201 0.0184) whereas for those with C*04:01, it appears a white ethnic background and a 202 more advanced age (≥65 years old) may be predisposing to ICU hospitalization (Figure
- 203 **2**; OR = 14.25 [12.24-16.26], FET p = 0.0053 and OR = 9.66 [8.27-11.05], FET p =
- 204 0.0188, respectively).

205 **DISCUSSION**

207	We have previously identified the DPA1*02:02 class II allele as being prevalent in two
208	other and independent cohorts, with patients of undisclosed ethnic background, but
209	hospitalized in Wuhan, China [19]. Of populations with reported allele frequencies and
210	an appreciable sampling size (≥100 individuals), only Hong Kong Chinese and
211	Japanese have DPA1*02:02 allele frequencies (55.8% and 43.5%, respectively; [25,26])
212	above its observed frequency (29.0%) in the COVID-19 positive cohort analyzed herein.
213	The frequency of this allele in other qualifying populations tends to be generally lower,
214	including in South African (Worcester, 15.6%), Norwegians (14.0%), Mexico Chiapas
215	Lacandon Mayans (6.7%), United Kingdom Europeans (4.3%) and Spain Navarre
216	Basques (2.2%). We note that the ethnic background of the Overmyer et al [20] cohort
217	is heterogeneous, and white individuals (of unknown ancestry) represent 45.1% and
218	(11/29) 37.9% of the COVID-19 positive cohort and its DPA1*02:02 subset,
219	respectively. In contrast, Asians represent only a minority of the cohort (1.9%) and
220	DPA1*02:02 subset (1/29~3.4%). It is important to note that, in the Overmyer cohort,
221	DPA1*02:02 is not statistically associated with increased risk of hospitalization. The
222	significant enrichment of this allele in the COVID-19 positive vs. negative cohorts (FET
223	p= 0.0174) across all individuals, but also when looking only at females (FET p= 0.0326)
224	or white individuals (FET p= 0.0491), and not any other demographics, may prove an
225	important disease marker, which would need to be validated with additional datasets
226	and in independent studies.

227 There are reports of disease associations with DPA1*02:02, DQA1*01:02, 228 C*04:01 and A*11:01, but they are few. Of note, the association of all aforementioned 229 alleles with narcolepsy [10,11] and a known trigger for this auto-immune disease 230 includes upper-airway infections and influenza vaccinations [27-32]. Susceptibility to 231 narcolepsy may in fact be an indirect effect of HLA class I and the HLA class II DP 232 isotype in response to viral and bacterial infections, including from influenza and 233 streptococcus [10,27,33,34]. It has since been reported that HLA-A*11 may be a 234 susceptibility allele to influenza A(H1N1)pdm09 infection in some populations [35] while 235 another report implicates HLA-I allele C*04:01 with high HIV viral loads [36]. Further, it 236 was recently demonstrated that MHC class II DR, DQ and DP isotypes play a role in mediating the cross-species entry of bat influenza viruses in vitro in human/animal cell 237 238 lines and in mice where engineered MHC-II deficiency made them resistant to upper-239 respiratory tract infections [12]. It is therefore not a stretch to envision an involvement 240 from these HLA class II isotypes in controlling the cellular entry of a broader range of 241 viral agents in vivo.

In a recent study examining HLA susceptibility based on SARS-CoV-2 derived peptide (epitope) binding strengths [37], the HLA-I allele A*11:01 was *in silico* predicted to bind a large number of SARS-CoV-2 derived peptides (n=750) with varying affinity [IC50 range 4.95 – 498.19, median = 149.62, mean = 182.28], and has been experimentally validated to bind SARS-CoV-2 peptide GLMWLSYFV (Tables S4 and S7 in Nguyen *et al.* [37]). In contrast, C*04:01 was only predicted *in silico* to bind six SARS-CoV-2 peptides and at higher IC50 ranges [167.65 – 469.30, median = 291.06, mean =

249 299.01] (Table S7 in Nguyen *et al.* [37]) suggesting a more limited ability to present
250 epitopes to T cells and mount an appropriate immune response.

251 There have been a number of reports published on HLA alleles - COVID-19 252 associations this past year, and on cohorts from many jurisdictions including China [18], 253 Italy [13,14,16] and the UK [17]. Wang et al. [18] compared the HLA allele frequencies 254 between a cohort of 82 Chinese individuals and a control population of bone marrow 255 donors previously studied by the same group. Novelli and co-workers [14] HLA typed a 256 cohort of 99 Italian COVID-19 patients, and associated the observed allele frequencies 257 with the HLA types in a reference group of 1,017 Italian individuals also previously 258 studied by the same group. Correale et al. [13] and Pisanti et al. [16] followed a different 259 strategy: these two independent studies leveraged population scale genomics data 260 retrieved from the Italian Bone-Marrow Donors Registry and the National Civil 261 Protection Department. They correlated background HLA allele frequency data with 262 mortality and morbidity rates across Italy to reach at starkly different conclusions on 263 which HLA alleles may play a role in disease etiology and progression. Disagreement 264 between these two studies (also distinct from the results of the other Italian study by 265 Novelli et al.) highlight the importance of large cohorts with matched samples to infer 266 the patient HLA alleles with better statistical significance. Poulton et al. [17] 267 characterized the HLA types of 80 COVID-19 patients in the UK on waiting lists for 268 transplantation, and compared observed allele frequencies in comparison to a cohort of 269 10,000 deceased organ donors and a separate cohort of 308 SARS-CoV-2-negative 270 individuals also on waiting lists for transplantation, the latter representing a matched 271 demographics for the COVID-19 patients in their cohort. Interestingly, this is the only

272 study that had any overlap between the alleles they flagged as being statistically 273 significant and the lists published by other studies cited above. Not surprisingly, the 274 alleles they listed do not intersect with the alleles identified and presented herein and 275 the three alleles we published earlier on a very small group of only eight patients. It is 276 nonetheless intriguing to find little to no HLA allele overlap between these reports, 277 including with those associated with the 2003 SARS outbreak, a related respiratory 278 disease caused by coronavirus [15,38,39]. This could be explained, at least partially, by 279 geographical differences and varying population allele frequencies in those cohorts, 280 relatively small cohort sizes (<100 patients), differences in experimentation setup and/or 281

other factors, including comorbidity status, that may be acting independently of HLA.

282 CONCLUSIONS

284	Here, we predict HLA-I and HLA-II alleles from publicly available COVID-19 patient
285	blood RNA-seq samples and identified several putative biomarkers. In a previous study,
286	we had observed one of these biomarkers (DPA1*02:02), and we postulate that patients
287	with the allele may have an increased susceptibility for COVID-19. Further, other alleles
288	(A11*01, C*04:01, DQA1*01:02) may be prognostic indicators of poor outcome.
289	However, although it is well established that patient HLA profiles play a significant role
290	in the onset and progression of infectious diseases in general, we caution against
291	drawing overreaching conclusions from regional, and often limited, observations. We
292	note that recently published studies associating HLA alleles and COVID-19, by and
293	large, disagree in their findings. We expect future studies with larger cohort sizes will
294	help bring a clearer picture of the role of patient HLA profiles, if any, in COVID-19
295	susceptibility and disease outcomes.

296 LIST OF ABBREVIATIONS

297

- 299 FET: Fisher's Exact Test; HFD-45: hospital-free days post 45 day followup (days); HLA:
- 300 human leukocyte antigen; ICU: Intensive Care Unit; KM: Kaplan-Meier

DECLARATIONS

- 302
- 303

304 Ethics approval and consent to participate

- 305 Not applicable
- 306

307 Consent for publication

- 308 Not applicable
- 309

310 Availability of data and materials

- 311 The RNA-seq datasets analysed during the current study are available in the ENA
- 312 repository https://www.ebi.ac.uk/ena/browser/view/PRJNA660067 accessions:
- 313 SRX9033799- SRX9033924. The associated clinical data are available in the GEO
- 314 repository <u>https://www.ncbi.nlm.nih.gov/geo</u> accession: GSE157103
- 315

316 **Competing interests**

317 The authors declare that they have no competing interests

318319 Funding

- 320 This work was supported by Genome BC and Genome Canada [281ANV]; and
- 321 the National Institutes of Health [2R01HG007182-04A1]. The content of this
- 322 paper is solely the responsibility of the authors, and does not necessarily
- 323 represent the official views of the National Institutes of Health or other funding
- 324 organizations.
- 325

326 Authors' contributions

- 327 RLW designed the study, analyzed the data and wrote the manuscript. IB participated in
- 328 the development of the study and co-wrote the manuscript.
- 329

330 Acknowledgements

331 Not applicable

332 **REFERENCES**

333

- 1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing
- 335 SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis.
- 336 2020;20:e238-e244.

337

- 338 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
- 339 Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20.

340

- 341 3. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL,
- 342 et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med.

343 2020;382:2302-15.

344

- 345 4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
- 346 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
- 347 Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25:2000180.

348

- 5. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation
- of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis.
- **351 2020;94:154-5**.

352

6. Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev
Immunol. 2018;18:325-39.

355 7. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity.
356 2012;37:426-40.

357

- 8. Chu X, Yang M, Song ZJ, Dong Y, Li C, Shen M, et al. Fine mapping MHC
- 359 associations in Graves' disease and its clinical subtypes in Han Chinese. J Med Genet.
- 360 2018;55:685-92.

361

- 362 9. Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA. The HLA class
- I A locus affects susceptibility to type 1 diabetes. Hum Immunol. 2002;63:657-64.

364

365 10. Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, et al. HLA-DPB1 and HLA

366 class I confer risk of and protection from narcolepsy. Am J Hum Genet. 2015;96:136-46.

367

368 11. Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, et al.

369 Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. Sleep.

2016;39:581-7.

371

12. Karakus U, Thamamongood T, Ciminski K, Ran W, Günther SC, Pohl MO, et al.

373 MHC class II proteins mediate cross-species entry of bat influenza viruses. Nature.

374 2019;567:109-12.

376	13. Correale P, Mutti L, Pentimalli F, Baglio G, Saladino RE, Sileri P, Giordano A. HLA-					
377	B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy. Int J Mol					
378	Sci. 2020;21:5205.					
379						
380	14. Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, et al.					
381	HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients.					
382	HLA. 2020; doi:10.1111/tan.14047.					
383						
384	15. Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role					
385	of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility					
386	and severity. Immunol Rev. 2020;296:205-19.					
387						
388	16. Pisanti S, Deelen J, Gallina AM, Caputo M, Citro M, Abate M, et al. Correlation of					
389	the two most frequent HLA haplotypes in the Italian population to the differential					
390	regional incidence of Covid-19. J Transl Med. 2020;18:352.					
391						
392	17. Poulton K, Wright P, Hughes P, Savic S, Welberry Smith M, Guiver M, et al. A role					
393	for human leucocyte antigens in the susceptibility to SARS-Cov-2 infection observed in					
394	transplant patients. Int J Immunogenet. 2020;47:324-8.					
395						
396	18. Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in					
397	82 Chinese individuals with coronavirus disease-2019 (COVID-19). HLA. 2020;96:194-					
398	6.					

399

400	19. Warren RL, Birol I. HLA	predictions from the bronchoalveolar	lavage fluid and blood

- 401 samples of eight COVID-19 patients at the pandemic onset. Bioinformatics. 2020;
- 402 doi:10.1093/bioinformatics/btaa756.

403

- 404 20. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et
- 405 al. Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Syst. 2020;
- 406 doi:10.1016/j.cels.2020.10.003.

407

408 21. Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType:

409 precision HLA typing from next-generation sequencing data. Bioinformatics.

410 2014;30:3310-6.

411

412 22. Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, et al. HLA typing

413 from RNA-Seq sequence reads. Genome Med. 2012;4:102.

414

415 23. Warren RL, Choe G, Freeman DJ, Castellarin M, Munro S, Moore R, Holt RA.

416 Derivation of HLA types from shotgun sequence datasets. Genome Med. 2012;4:95.

417

- 418 24. Valenzuela, C. Dos soluciones para la estimación de "odds ratios" con ceros [2
- 419 solutions for estimating odds ratios with zeros]. Rev Med Chil. 1993;121:1441-4.

- 421 25. Gonzalez-Galarza FF, McCabe A, Santos EJ, Jones J, Takeshita LY, Ortega-Rivera
- 422 ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data
- 423 classification, open access genotype data and new query tools. Nucleic Acid Research.
- 424 **2020;48:D783-8**.
- 425
- 426 26. Allele frequency net database. <u>http://allelefrequencies.net/</u>
- 427
- 428 27. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is
- 429 seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol.
- 430 2011;70:410-7.
- 431

432 28. Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J, et al. Genome wide analysis of

433 narcolepsy in China implicates novel immune loci and reveals changes in association

434 prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet.

435 **2013;9:e1003880**.

436

437 29. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter

438 J. Incidence of narcolepsy in Norwegian children and adolescents after vaccination

439 against H1N1 influenza A. Sleep Med. 2013;14:867-71.

440

441 30. Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, et al.

442 Correlation between human leukocyte antigen class II alleles and HAI titers detected

443 post-influenza vaccination. PLoS One. 2013;8:e71376.

444

445	31. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, et al. Risk
446	of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic
447	influenza vaccine in Quebec. PLoS One. 2014;9:e108489.
448	
449	32. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The
450	incidence of narcolepsy in Europe: before, during, and after the influenza
451	A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31:1246-54.
452	
453	33. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-
454	streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979-
455	83.
456	
457	34. Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy.
458	Curr Opin Neurobiol. 2013;23:767-73.
459	
460	35. Dutta M, Dutta P, Medhi S, Borkakoty B, Biswas D. Polymorphism of HLA class I
461	and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam,
462	Northeast India. J Med Virol. 2018;90:854-60.
463	
464	36. Olvera A, Pérez-Álvarez S, Ibarrondo J, Ganoza C, Lama JR, Lucchetti A, et al. The
465	HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with
466	high population frequency drive rate of HIV disease progression. AIDS. 2015;29:507-17.

- 468 37. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF.
- 469 Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome
- 470 Coronavirus 2. J Virol. 2020;94:e00510-20.
- 471
- 472 38. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, et al. Association of HLA
- 473 class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet.
- 474 2003;4:9.
- 475
- 476 39. Sanchez-Mazas A. HLA studies in the context of coronavirus outbreaks. Swiss Med
- 477 Wkly. 2020;150:w20248.

478 **TABLES**

479

- 480 **Table 1**. HLA-I alleles identified in 10% or more COVID-19 positive patients and
- 481 statistical tests of enrichment in the Overmyer *et al.* [20] COVID-19 positive (vs.
- 482 negative) cohort and association with hospitalization. Red font indicates significant
- 483 associations (Fisher's Exact Test) not corrected for multiple hypothesis tests.

HLA-I	COVID+ patients	ICU- patients	ICU+ patients	COVID- patients	H1: Enriched in COVID+ Fisher's Exact Test p-value	H1: Increased risk of hospitalization Fisher's Exact Test p-value
A*02:01	30	15	15	12	0.9614	0.5862
A*24:02	23	12	11	6	0.6161	0.5000
C*07:02	22	9	13	7	0.7890	0.8865
C*07:01	18	6	12	7	0.8991	0.9668
C*04:01	18	4	14	3	0.3231	0.0087
C*06:02	16	8	8	6	0.8708	0.6071
B*51:01	16	6	10	2	0.2292	0.9143
C*03:04	14	4	10	3	0.5171	0.9796
C*15:02	14	6	8	1	0.1363	0.8060
A*01:01	13	5	8	7	0.9742	0.8832
A*03:01	13	7	6	5	0.8680	0.5000
A*30:02	13	7	6	0	0.0417	0.5000
B*07:02	12	5	7	5	0.8969	0.8217
A*30:01	12	8	4	1	0.2016	0.1783
B*44:02	11	4	7	4	0.8320	0.9001
A*68:01	11	5	6	0	0.0697	0.7377
A*11:01	10	1	9	2	0.5320	0.0078

484

485

- 487 Table 2. HLA-II alleles identified in 10% or more COVID-19 positive patients and
- 488 statistical tests of enrichment in the Overmyer *et al.* [20] COVID-19 positive (vs.
- 489 negative) cohort and association with hospitalization. Red font indicates significant
- 490 associations (Fisher's Exact Test) not corrected for multiple hypothesis tests.

HLA-II	COVID+ patients	ICU- patients	ICU+ patients	COVID- patients	H1: Enriched in COVID+ Fisher's Exact Test p-value	H1: Increased risk of hospitalization Fisher's Exact Test p-value
DPA1*01:03	46	21	25	17	0.9812	0.8421
DQA1*01:02	40	26	14	10	0.5363	0.0121
DPB1*04:01	22	9	13	10	0.9726	0.8865
DPA1*02:02	29	16	13	2	0.0174	0.3299
DPA1*02:01	22	11	11	6	0.6578	0.5952
DQA1*05:02	19	9	10	3	0.2824	0.6945
DPB1*01:01	19	10	9	3	0.2824	0.5000
DQB1*06:11	11	6	5	3	0.6811	0.5000
DRB1*13:01	10	7	3	4	0.8689	0.1589
DQB1*06:02	10	6	4	3	0.7348	0.3703
DRB1*15:01	10	4	6	2	0.5320	0.8411

491

492

494 **FIGURES**











506 Figure 2. HLA alleles – demographics combinations with diagnostic (bottom) or 507 prognostic (top) potential in a COVID-19 cohort. We calculated the odds ratio (OR) 508 for each HLA-I and HLA-II alleles observed in 10% or more of patients, and plotted OR 509 and the influence of demographics for HLA alleles showing significant associations 510 (from Tables 1 and 2). First, looking at the influence of demographic characteristics 511 such as sex (male/female), age (65 years old or above/less than 65 years old) and 512 ethnicity (minority/white ethnic background) on the susceptibility of patients with these 513 alleles to test positive for COVID-19 (lower two panels), and on the risk associated with 514 ICU hospitalization (upper three panels). Red asterisks indicate significant demographic 515 characteristics (Fisher's Exact Test) not corrected for multiple hypothesis tests.